VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Stewartsville, NJ, US. The stock last traded at $28.56, up 0.00% on the session, giving a market capitalisation of $19.1M. On trailing twelve-month figures it carries a trailing P/E of -1.18, a net margin of -4726.2%. Its beta of 2.01 implies it has historically moved more than the broad market.
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
VYNE Therapeutics Inc. is most often compared with the following Healthcare names: